Adagrasib is an experimental Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitor being investigated for the treatment of KRASG12C mutant lung and colon adenocarcinomas. Adagrasib is an orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity (2, 4). Normally, guanosine triphosphate (GTP) binds to KRAS, activating the protein and promoting effectors to the mitogen-activated protein (MAP) kinase pathway. Guanosine triphosphate (GTP) is hydrolyzed to guanosine diphosphate (GDP), and KRAS is inactivated. Kirsten rat sarcoma viral oncogene homolog (KRAS)G12C mutations impair hydrolysis of GTP, leaving it in the active form.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Adagrasib, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.